Ozempic and Mounjaro
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.
Weight-loss drugs may cut breast cancer risk by up to 30%, study finds
Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study. Women who take GLP-1 medications, such as Ozempic or Mounjaro, are less likely to develop breast cancer, a new study has found. The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, come from an analysis of more than 110,000 women aged between 45 and 80.
Is the growing use of GLP-1s reshaping ideas of Black beauty?
People across the Black diaspora are increasingly turning to weight-loss drugs. How might this reshape our health, wellbeing and body image?Don’t get The Long Wave delivered to your inbox? Sign up hereThese days, I barely make it through the week without seeing news about what weight-loss medications, such as Ozempic and Mounjaro, can now supposedly achieve.
Is the growing use of GLP-1s reshaping ideas of Black beauty?
People across the Black diaspora are increasingly turning to weight-loss drugs. How might this reshape our health, wellbeing and body image?Don’t get The Long Wave delivered to your inbox? Sign up hereThese days, I barely make it through the week without seeing news about what weight-loss medications, such as Ozempic and Mounjaro, can now supposedly achieve.
Certain tortillas are now being marketed as ‘GLP-1 friendly.’ What does that even mean?
Certain tortillas are now being marketed as ‘GLP-1 friendly.’ What does that even mean? While a ‘GLP-1 friendly’ label may seem arbitrary, some medical experts say it may make people pay closer attention to what they’re eating - Bookmark - CommentsGo to comments Food manufacturers are trying to cash in on the popularity of weight-loss medications such as Ozempic and Mounjaro, with a growing number of easy, grab-and-go meals and snacks being sold as “GLP-1 friendly.”
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky The same drug that is helping patients manage diabetes and reduce their risk of serious complications from chronic conditions is also being discussed as a beauty hack by people hoping to lose a few kilograms. Experts say more education and awareness are needed.
Weight-loss jabs could slash cancer risk 41 per cent, experts say
Weight-loss jabs could slash cancer risk 41 per cent, experts say A major new study looks at thousands of people taking the medication Weight loss jabs could should be investigated as potential “cancer prevention agents”, experts have said after a study linked the medication to a reduced risk of cancers linked to obesity. Being overweight or obese has been linked to an increased risk of 13 types of cancer including of the breast, bowel, pancreas, kidney, liver and stomach. Glucagon-like...
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports
Retatrutide, a triple action treatment for type 2 diabetes, could significantly reduce blood glucose concentrations and body weight in patients with the condition, a phase 3 trial has reported. The results, published in the Lancet,1 show that patients who received injections of retatrutide for 40 weeks lost more than four times as much weight as those in the placebo group. After 40 weeks the average reduction in HbA1c with the new treatment was more than twice that in the placebo group,...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...